Public recall detail

Archived - Important Safety Information Regarding Early Virologic Non-response in Patients with HIV Infection Treated with 3TC® (lamivudine), Ziagen® (abacavir) and VireadTM (tenofovir) - GlaxoSmithKline Inc.

medium
Recall Safety notice
Quick summary

Quick summary: Archived - Important Safety Information Regarding Early Virologic Non-response in Patients with HIV Infection Treated with 3TC® (lamivudine), Ziagen® (abacavir) and VireadTM (tenofovir) - GlaxoSmithKline Inc. .

Recommended action

Recommended action: compare your product with the official notice and follow the instructions published by the official source.

Recall details

Quick summary: Archived - Important Safety Information Regarding Early Virologic Non-response in Patients with HIV Infection Treated with 3TC® (lamivudine), Ziagen® (abacavir) and VireadTM (tenofovir) - GlaxoSmithKline Inc. .

Official details

Affected product details

Structured information extracted from the official recall notice. Confirm the identifiers and instructions in the original notice.

Brand
ProductPlace of origin xx

Affected products

ProductPlace of origin xx
DescriptionProduct Place of origin xx
Additional official information
Background{}
Companies
Audiences

Contains information licensed under the Open Government Licence – Canada. SafetyPulse is independent of the Government of Canada.

Official source Monitor products Back to recalls

Starting...

Related recalls

Similar recalls and safety notices.

Loading related recalls...